Vertex Pharmaceuticals

Q: What is Vertex Pharmaceuticals competition?

Vertex Pharmaceuticals top competitors include: Alexion , Incyte , Alnylam Pharmaceuticals , Regeneron Pharmaceuticals

Business Services · Massachusetts, United States · 5,400 Employees

View Company Info for Free

About

Headquarters

50 Northern Ave, Boston, Massachusetts, 02210, ...

Phone Number

(617) 341-6100

Website

www.vrtx.com

Revenue

$10.3 Billion

Stock Symbol

VRTX

Industry

Business Services General

Business Services

Most Recent Scoops

Dec 9 2024

Open Position

Vertex Pharmaceuticals is currently seeking a Clinical Development Associate Medical Director, Pain. (Boston, Massachusetts, United States)

Dec 9 2024

Open Position

Vertex Pharmaceuticals is currently seeking a Associate Director, Strategy & Operations. (Japan)

See all scoops

Highlights

$2.5B

Total Funding Amount

$400M

Most Recent Funding Amount

Number of Funding Rounds

View details

Who is Vertex Pharmaceuticals

Founded in 1989, Vertex Pharmaceuticals is a global biotechnology company focused on the discovery, development and commercialization of drugs for a range of serious diseases. Located in Boston, Massachusetts.Explore more

Is this data correct?

View contact profiles from Vertex Pharmaceuticals

Popular Searchesvertex pharmaceuticals IncVertex PharmaceuticalsVertex Pharmaceuticals( IncVertex Pharmaceuticals (UK) LtdVetex IncSIC Code 87,873NAICS Code 54,541Ticker NASDAQ: VRTXShow more

Vertex Pharmaceuticals Org Chart

Reshma Kewalramani

President & Chief Executive Officer

Phone

Stuart Arbuckle

Executive VP & Chief Operating Officer

Phone

Stephanie Franklin

Senior VP & Chief Human Resources Officer

Phone

Is Vertex Pharmaceuticals your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Last 7 days

Competitive Alert! Recent activity has been detected by your competitor Masked Content

Check if Vertex Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!

Click to see if Vertex Pharmaceuticals had a recent Job posting/layoffs

Vertex Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic

Earning: See what the market has to say on Vertex Pharmaceuticals recently announced quarterly report

Check out if Vertex Pharmaceuticals is spiking on competitors!

Website visits: Recent activity has been detected on your website

Product Launch: Get notified when Vertex Pharmaceuticals launches new products

Congratulate Masked Content for being promoted to Masked Content at Vertex Pharmaceuticals

Funding: Get notified immidiatlly once Vertex Pharmaceuticals has new funding data

Recommended Actions

Reach out to Masked Content who joined Vertex Pharmaceuticals as Masked Content

Find 2 more new buyers

Compare Similar Companies to Vertex Pharmaceuticals

Compare insights from companies similar to Vertex Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

Vertex Pharmaceuticals

$10.3B

5.4K

Regeneron Pharmaceuticals

$13.5B

13.9K

Biogen

$9.6B

7.6K

Incyte

$4.1B

2.5K

Jazz Pharmaceuticals

$3.9B

2.8K

Alnylam Pharmaceuticals

$2.3B

2.1K

Alexion

$1.4B

Compare CEO

How does Reshma Kewalramani compare against Competing Companies' CEOs?

Reshma Kewalramani

President & Chief Executive Officer at Vertex...

Top 5%

CEO effectiveness to drive business results

Excellent

100%

Good

Average

Poor

Very Bad

CEO management style

Good

100%

Bad

VS.

Tassos Gianakakos

CEO at MyoKardia

CEO effectiveness to drive business results

Excellent

100%

Good

Average

Poor

Very Bad

CEO management style

Good

100%

Bad

Select a different CEO to compare

Tassos Gianakako...

CEO at MyoKardia

Rick Fair

CEO at Bellicum

View Email Formats for Vertex Pharmaceuticals

Vertex Pharmaceuticals financials insights

Gather financial insights about Vertex Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.

Graph showing recent funding, most recent acquisition, and main investor information for Vertex Pharmaceuticals.

See All Financials Insights

Vertex Pharmaceuticals Employee Growth Rate

Graph showing projected employee growth data for Vertex Pharmaceuticals

View Vertex Pharmaceuticals’s full employee growth data

Percentage of growth

1st year Mask

2nd year Mask

Vertex Pharmaceuticals Tech Stack

A closer look at the technologies used by Vertex Pharmaceuticals

IT2

CSC Corporate Domains

CSC

See more technologies

Most Recent Scoops

Dec 9 2024

Open Position

Vertex Pharmaceuticals is currently seeking a Clinical Development Associate Medical Director, Pain. (Boston, Massachusetts, United States)

Dec 9 2024

Open Position

Vertex Pharmaceuticals is currently seeking a Associate Director, Strategy & Operations. (Japan)

Dec 6 2024

Open Position

Vertex Pharmaceuticals is currently seeking a Clinical Development Senior Medical Director, Transplant Immunology. (Boston, Massachusetts, United States)

Dec 6 2024

Open Position

Vertex Pharmaceuticals is currently seeking a Associate Director, Market Access Analytics. (Boston, Massachusetts, United States)

Dec 5 2024

Open Position

See more scoops

Vertex Pharmaceuticals News & Media

Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor / deutivacaftor), a once-daily triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. Vertex raised its CF patient estimates
Jan 14, 2025
finance.yahoo.com
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Hosts 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.
Jan 13, 2025
seekingalpha.com
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 a.m. ET/7:30 a.m. PT. “2024 marked another year of excellent progress for Vertex, as we reached more people with CF than ever before, began a new era of commercial diversification, and advanced and b
Jan 12, 2025
www.businesswire.com
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
SHANGHAI & CAMBRIDGE, Mass. & BOSTON--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and
Jan 10, 2025
www.businesswire.com
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
BOSTON & SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and
Jan 10, 2025
www.businesswire.com

Top Companies in United States

Frequently Asked Questions Regarding Vertex Pharmaceuticals

Where is Vertex Pharmaceuticals located?

Vertex Pharmaceuticals's headquarters are located at 50 Northern Ave, Boston, Massachusetts, 02210, United States

What is Vertex Pharmaceuticals's phone number?

Vertex Pharmaceuticals's phone number is (617) 341-6100

What is Vertex Pharmaceuticals's stock symbol?

Vertex Pharmaceuticals's stock symbol is VRTX

What is Vertex Pharmaceuticals's official website?

Vertex Pharmaceuticals's official website is www.vrtx.com

What is Vertex Pharmaceuticals's Revenue?

Vertex Pharmaceuticals's revenue is $10.3 Billion

What is Vertex Pharmaceuticals's SIC code?

Vertex Pharmaceuticals's SIC: 87,873

What is Vertex Pharmaceuticals's NAICS code?

Vertex Pharmaceuticals's NAICS: 54,541

How many employees does Vertex Pharmaceuticals have?

Vertex Pharmaceuticals has 5,400 employees

What industry does Vertex Pharmaceuticals belong to?

Vertex Pharmaceuticals is in the industry of: Business Services General, Business Services

What is Vertex Pharmaceuticals competition?

Vertex Pharmaceuticals top competitors include: Alexion, Incyte, Alnylam Pharmaceuticals, Regeneron Pharmaceuticals

What companies has Vertex Pharmaceuticals acquired?

Vertex Pharmaceuticals has acquired the companies: Aurora Biosciences, ViroChem Pharma, Nivalis Therapeutics, Exonics Therapeutics

What technology does Vertex Pharmaceuticals use?

Some of the popular technologies that Vertex Pharmaceuticals uses are: Solidworks, goo.gl, IT2, CSC Corporate Domains

Who is the CEO of Vertex Pharmaceuticals?

Vertex Pharmaceuticals's CEO is Reshma Kewalramani

Who is the CFO of Vertex Pharmaceuticals?

Vertex Pharmaceuticals's CFO is Charles Wagner

How do I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals contact info: Phone number: (617) 341-6100 Website: www.vrtx.com

What does Vertex Pharmaceuticals do?

What are Vertex Pharmaceuticals social media links?

Vertex Pharmaceuticals Linkedin page Vertex Pharmaceuticals Twitter page

How much funding has Vertex Pharmaceuticals raised to date?

Vertex Pharmaceuticals has raised $2.5 Billion in 11 funding rounds

When was the last funding round for Vertex Pharmaceuticals?

Vertex Pharmaceuticals closed its last funding round on Sep 24, 2010 with the amount of $400 Million

Who invested in Vertex Pharmaceuticals?

Vertex Pharmaceuticals has 11 investors including Undisclosed, Cystic Fibrosis Foundation Therapeutics Inc., Undisclosed and Undisclosed.

Is Vertex Pharmaceuticals a public company?

Yes, Vertex Pharmaceuticals is a public company and is traded under the symbol VRTX

See more information about Vertex Pharmaceuticals

Vertex Pharmaceuticals Latest Hires and Their Positions

Vertex Pharmaceuticals is expanding and recently hired new employees. Here are the latest additions to the team.

Golby Fnkf

Joined Dec 15, 2024

Phone

Golby Jalali

Joined Dec 15, 2024

Phone

Jiahe Li

Joined Dec 15, 2024

Phone

Kate Carter

Director, Marketing

Joined Dec 12, 2024

Phone

Sell Smarter. Win Faster.

Level up your game to ZoomInfo Copilot, intuitive AI that turns your data and high-quality ZoomInfo data into an unfair advantage for your go-to-market teams.